IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Means Investment CO. Inc.

Means Investment CO. Inc. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,334 shares of the company’s stock after selling 45 shares during the quarter. Means Investment CO. Inc.’s holdings in IDEXX Laboratories were worth $1,378,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in IDXX. International Assets Investment Management LLC lifted its stake in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after acquiring an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $113,104,000. Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after acquiring an additional 213,731 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 230.1% during the third quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after purchasing an additional 76,809 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.5 %

IDXX opened at $422.05 on Monday. The company has a market capitalization of $34.56 billion, a PE ratio of 40.70, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The business has a 50-day moving average of $424.12 and a 200-day moving average of $453.85.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the company earned $2.53 earnings per share. The company’s revenue was up 6.6% compared to the same quarter last year. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IDXX. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Piper Sandler reissued a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $517.29.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.18% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.